title: Treatment options expanding for advanced melanoma.
abstract: Immunotherapies and BRAF and MEK inhibitors have dramatically improved outcomes in advanced melanoma. The availability of these novel approaches has necessitated changes to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). The NCCN Guidelines feature algorithms that aid clinicians in selecting initial therapy, which now includes anti-programmed death protein receptor-1 PD-1 inhibitors among the recommended systemic therapy options for patients with metastatic or unresectable disease.
authors.affiliation: Presented by John A. Thompson, MD, Co-Director of the Melanoma Clinic at the Seattle Cancer Care Alliance and Professor of Medical Oncology at the University of Washington School of Medicine, Seattle, Washington.
authors.forename: John A
authors.initials: JA
authors.lastname: Thompson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008495:Medical Oncology / Q000592:standards; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf